CSL: how a government lab became one of the world's great biotech companies

There is a building on Poplar Road in Parkville, Melbourne, that has been making things to keep people alive since the 1920s. The sign out front has changed a few times over the decades. The work, give or take the revolution in molecular biology, largely hasn't. CSL Limited — Commonwealth Serum Laboratories in a previous life — manufactures blood-plasma therapies, influenza vaccines and recombinant proteins at scale for the world. It is one of the largest companies on the ASX by market capitalisation, consistently trading above $100 billion in recent years. It derives the overwhelming bulk of its revenue from overseas. And yet it started as a government agency whose founding brief was to stop Australians dying from diphtheria.

I've spent a fair bit of time with this company's history, partly because it's genuinely fascinating and partly because it is the kind of story that doesn't get told often enough: a privatisation that actually worked, followed by a series of acquisitions that were, against most odds, well-timed and well-executed. That combination is rare enough to deserve serious attention.

The Commonwealth Serum Laboratories: government science as public health infrastructure

CSL was established in 1916 under the Department of Health, created to produce biological products — sera, vaccines, antitoxins — that Australia could not reliably import during wartime. The original rationale was essentially strategic: if shipping lanes were cut off, Australians would need their own supply of life-saving biologicals. For much of its early history the organisation operated as a kind of public health utility, producing tetanus antitoxin, smallpox vaccine, and sera for snake bite and diphtheria.

For decades the operation ticked along. It was modestly funded, staffed by scientists, and not particularly well known outside the medical community. It was not designed to compete globally or generate returns for shareholders. It was designed to keep the lights on in an emergency, and in that narrow sense it did its job.

By the 1980s, though, the logic of government ownership was under strain. The Hawke and Keating governments were systematically reviewing Commonwealth assets — asking which ones genuinely needed to be in public hands and which ones were just there by historical inertia. CSL fell into scope. The assessment was that the biologicals sector had enough private-sector depth globally that a standalone, commercially oriented Australian company could compete. In 1994, under the Keating government, Commonwealth Serum Laboratories was corporatised, renamed CSL Limited, and listed on the ASX at $2.30 per share.

That original $2.30 is worth keeping in mind every time you check the current price.

The early years: building commercial discipline

Privatisation is a process, not an event. CSL spent most of the late 1990s building the commercial infrastructure that government ownership had never required — a genuine sales force, cost discipline, a strategy for international markets. The company was profitable but not spectacular. It had revenue from plasma products, vaccines and diagnostics, but its scale was small relative to the global plasma industry, which by the mid-1990s was dominated by large American and European players.

Brian McNamee, who became chief executive in 1990 and held the role for more than two decades, is the person most associated with the transformation that followed. Under his stewardship the company moved from a domestic biologicals producer to a genuine global competitor. The short version is that McNamee understood early that plasma fractionation — the process of separating blood plasma into its constituent therapeutic proteins — is a scale business. The bigger your plasma collection network, the lower your unit cost, the stronger your position in the global immunoglobulin and albumin markets. Small players would be outcompeted or absorbed. CSL needed to get bigger, and it needed to do so before the window closed.

The ZLB acquisition: the move that changed everything

In 2000, CSL acquired the plasma business of the Swiss Red Cross — operating under the name ZLB Bioplasma — for what was reported at the time to be roughly $900 million. It was a big number for a company of CSL's size then. It was also, in retrospect, one of the best-timed acquisitions in Australian corporate history.

The Swiss Red Cross had been caught up in the contaminated blood scandal that swept through European blood services in the late 1980s and 1990s. A substantial proportion of haemophilia patients across multiple countries had been infected with HIV and hepatitis C through contaminated plasma products, a public health catastrophe that prompted massive regulatory reform globally. The Red Cross, facing legal liability and reputational damage, was looking to exit commercial plasma operations. CSL was a buyer at the right moment.

ZLB brought CSL a significant European plasma collection and fractionation infrastructure, a manufacturing base in Berne, and access to distribution networks in markets CSL could not previously reach. It roughly doubled the company's revenue and transformed it into a genuinely international operation almost overnight. I'll admit the timing element here looks a bit lucky in hindsight — but McNamee's team still had to execute the integration, and by most accounts they did.

Aventis Behring and the establishment of global scale

Three years later, in 2004, CSL went back to the acquisition table. It purchased Aventis Behring — the plasma business being divested from the French pharmaceutical company Aventis as part of its own merger with Sanofi — for approximately $925 million. Aventis Behring brought plasma collection centres across the United States, a substantial American manufacturing footprint, and the Beriplast and Humate-P product lines, among others.

Combined with ZLB, this made CSL one of the three largest plasma fractionators in the world, alongside Baxter International's Baxalta division and Grifols of Spain. The company reorganised its plasma businesses under the CSL Behring brand, which remains the core of its operations today.

Getting to global scale in plasma fractionation matters for a structural reason: immunoglobulin (IG) therapy, used to treat a range of immune deficiencies and autoimmune conditions, has been growing in demand for decades as new indications are identified and as ageing populations in wealthy countries develop more immune-related conditions. The companies with large, geographically diversified plasma collection networks and efficient fractionation capacity are structurally advantaged in this market. By the mid-2000s, CSL had built exactly that.

Seqirus and the influenza vaccines business

The other leg of CSL's global business is influenza vaccines, now operated through its subsidiary Seqirus. This arm has a messier history. CSL had long been a significant influenza vaccine manufacturer — its origins in public health biologicals gave it early capability here — but the business required substantial capital investment to modernise production facilities from egg-based to cell-based and recombinant manufacturing methods.

In 2015 CSL acquired the influenza vaccines business of Novartis for roughly US$275 million, folding it into a new entity called Seqirus. The Novartis acquisition brought manufacturing facilities in Liverpool in the UK and Holly Springs in North Carolina, as well as cell-based influenza vaccine technology. CSL's stated ambition was to consolidate the fragmented influenza vaccine market and shift production toward next-generation manufacturing methods that are faster and less dependent on the annual egg-allocation process.

Seqirus has been slower to generate returns than CSL Behring. The influenza vaccine business is inherently lumpy — demand surges in bad flu years and softens in mild ones — and the capital intensity of building new manufacturing capacity is substantial. The COVID-19 pandemic briefly complicated the picture, then clarified it: Seqirus became one of the manufacturers of the AstraZeneca vaccine in Australia under a federal government agreement, which kept its facilities running at high utilisation during a period when flu vaccine volumes were compressed by global lockdowns. Seqirus has since moved toward profitability on a more consistent basis, though I'd argue the market still tends to undervalue this division relative to its long-term strategic position in pandemic preparedness.

CSL112 and the pipeline: betting on the next platform

CSL's most significant near-term pipeline asset has been CSL112, a recombinant apolipoprotein A-I product designed to reduce the risk of recurrent major cardiovascular events after a heart attack. The company invested substantially in a large Phase III clinical trial called AEGIS-II, which enrolled tens of thousands of patients across dozens of countries. The trial results, reported in 2023, did not meet the primary endpoint — a disappointment that was reflected immediately in the company's share price.

That kind of setback is an ordinary part of biotech development, though it's expensive. CSL has maintained that its broader pipeline — including gene therapy assets and next-generation plasma fractionation technologies — provides sufficient runway. The Vifor Pharma acquisition, completed in 2022 for approximately US$11.7 billion, extended the company into iron deficiency and kidney disease, adding another therapeutic platform to reduce its dependence on plasma alone.

Vifor has been a more contentious bet. Several analysts have questioned whether the acquisition price was full, and integration of a Swiss-based nephrology business into CSL's plasma-centric structure has taken time. The company's chief executive Paul McKenzie, who succeeded Paul Perreault in 2022, has publicly committed to extracting value from the acquisition over the medium term. Whether that plays out is genuinely uncertain.

What the CSL story actually tells us

CSL is frequently cited alongside Cochlear's competitive moat story as evidence that Australian companies can build durable global positions in complex, science-intensive industries. The comparison is apt. Both companies built their early advantage from publicly funded research and government-backed manufacturing capability, then used privatisation or commercialisation as a springboard to acquire global scale before their respective markets consolidated.

The difference is that CSL's path required much larger capital deployments and carried more execution risk. The ZLB and Aventis Behring acquisitions were, by Australian corporate standards, enormous bets. They paid off because the plasma fractionation market did consolidate, demand for immunoglobulin therapies did keep growing, and CSL's operational integration was competent rather than catastrophic. Those outcomes were not guaranteed.

For a fuller picture of how Australian companies have built global technical positions from relatively small domestic bases — and the broader landscape of what that requires — the Outliers & Global Empires section is worth working through systematically.

The original $2.30 IPO price is, by the way, now roughly equivalent to about one five-hundredth of the current share price on a split-adjusted basis. The Commonwealth of Australia sold something that turned out to be extraordinarily valuable. Whether that's a story about a privatisation that was too cheap, or simply a story about what can happen when a company gets the strategy right over thirty years, probably depends on your prior views about government ownership. I don't think there's a clean answer. But the company that came out the other side is genuinely impressive, and the numbers say so plainly enough.